HC Wainwright set a $4.00 price target on Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) in a research report released on Friday, TipRanks reports. The brokerage currently has a buy rating on the biotechnology company’s stock.
Separately, Zacks Investment Research raised Trillium Therapeutics from a hold rating to a buy rating and set a $0.75 target price for the company in a report on Thursday, April 25th.
TRIL stock opened at $0.63 on Friday. The company has a market cap of $13.38 million, a P/E ratio of -0.27 and a beta of 2.22. Trillium Therapeutics has a twelve month low of $0.51 and a twelve month high of $7.00.
Several institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC boosted its stake in shares of Trillium Therapeutics by 164.0% in the 4th quarter. Geode Capital Management LLC now owns 26,627 shares of the biotechnology company’s stock worth $45,000 after buying an additional 16,541 shares during the last quarter. Two Sigma Investments LP purchased a new stake in Trillium Therapeutics during the fourth quarter worth $35,000. Jane Street Group LLC acquired a new position in shares of Trillium Therapeutics during the fourth quarter worth $43,000. Oxford Asset Management LLP increased its position in shares of Trillium Therapeutics by 64.0% during the first quarter. Oxford Asset Management LLP now owns 93,589 shares of the biotechnology company’s stock worth $62,000 after purchasing an additional 36,534 shares in the last quarter. Finally, Morgan Stanley increased its position in shares of Trillium Therapeutics by 25.2% during the third quarter. Morgan Stanley now owns 356,655 shares of the biotechnology company’s stock worth $2,068,000 after purchasing an additional 71,860 shares in the last quarter. 27.22% of the stock is owned by institutional investors and hedge funds.
About Trillium Therapeutics
Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trials for advanced hematologic malignancies, and solid tumors and mycosis fungoides.
Further Reading: What is the downside to momentum investing?
Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.